Medicare Payment for Opioid Treatment Programs.

IF 9.5 Q1 HEALTH CARE SCIENCES & SERVICES JAMA Health Forum Pub Date : 2024-07-05 DOI:10.1001/jamahealthforum.2024.1907
Carter H Nakamoto, Haiden A Huskamp, Julie M Donohue, Michael L Barnett, Adam J Gordon, Ateev Mehrotra
{"title":"Medicare Payment for Opioid Treatment Programs.","authors":"Carter H Nakamoto, Haiden A Huskamp, Julie M Donohue, Michael L Barnett, Adam J Gordon, Ateev Mehrotra","doi":"10.1001/jamahealthforum.2024.1907","DOIUrl":null,"url":null,"abstract":"<p><strong>Importance: </strong>Medicare began paying for medications for opioid use disorder (MOUD) at opioid treatment programs (OTPs) that dispense methadone and other MOUD in January 2020. There has been little research describing the response to this payment change and whether it resulted in more patients receiving MOUD or just a shift in who pays for this care.</p><p><strong>Objective: </strong>To describe how many and which Medicare beneficiaries receive care from OTPs and how this compares to those receiving MOUD in other settings.</p><p><strong>Design, setting, and participants: </strong>This cross-sectional study included all patients receiving MOUD care identified in 2019-2022 100% US Medicare Parts B and D claims. Patients receiving care in an OTP who were dually insured with Medicare and Medicaid in the 2019-2020 Transformed Medicaid Statistical Information System were also included.</p><p><strong>Exposure: </strong>Receiving MOUD care in an OTP.</p><p><strong>Main outcomes and measures: </strong>Comparisons of 2022 beneficiaries treated in OTPs vs other non-OTP settings in 2022.</p><p><strong>Results: </strong>The share of Medicare beneficiaries treated by OTPs rose steadily from 4 per 10 000 (14 160 beneficiaries) in January 2020 to 7 per 10 000 (25 596 beneficiaries) in August 2020, then plateaued through December 2022; of 38 870 patients (23% ≥66 years; 35% female) treated at an OTP in 2022, 96% received methadone. Patients in OTPs, compared to those receiving MOUD in other settings, were more likely be 65 years and younger (65% vs 62%; P < .001), less likely to be White (72% vs 82%; P < .001), and more likely to be an urban resident (86% vs 74%; P < .001). When Medicare OTP coverage began, there was no associated drop in the number of dually insured patients with Medicaid with an OTP claim. Of the 1854 OTPs, 1115 (60%) billed Medicare in 2022, with the share billing Medicare ranging from 13% to 100% across states.</p><p><strong>Conclusions and relevance: </strong>This study showed that since the initiation of Medicare OTP coverage in 2020, there has been a rapid increase in the number of Medicare beneficiaries with claims for OTP services for MOUD, and most OTPs have begun billing Medicare. Patients in OTPs were more likely to be urban residents and members of racial or ethnic minority groups than the patients receiving other forms of MOUD.</p>","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"5 7","pages":"e241907"},"PeriodicalIF":9.5000,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11259898/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA Health Forum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1001/jamahealthforum.2024.1907","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Importance: Medicare began paying for medications for opioid use disorder (MOUD) at opioid treatment programs (OTPs) that dispense methadone and other MOUD in January 2020. There has been little research describing the response to this payment change and whether it resulted in more patients receiving MOUD or just a shift in who pays for this care.

Objective: To describe how many and which Medicare beneficiaries receive care from OTPs and how this compares to those receiving MOUD in other settings.

Design, setting, and participants: This cross-sectional study included all patients receiving MOUD care identified in 2019-2022 100% US Medicare Parts B and D claims. Patients receiving care in an OTP who were dually insured with Medicare and Medicaid in the 2019-2020 Transformed Medicaid Statistical Information System were also included.

Exposure: Receiving MOUD care in an OTP.

Main outcomes and measures: Comparisons of 2022 beneficiaries treated in OTPs vs other non-OTP settings in 2022.

Results: The share of Medicare beneficiaries treated by OTPs rose steadily from 4 per 10 000 (14 160 beneficiaries) in January 2020 to 7 per 10 000 (25 596 beneficiaries) in August 2020, then plateaued through December 2022; of 38 870 patients (23% ≥66 years; 35% female) treated at an OTP in 2022, 96% received methadone. Patients in OTPs, compared to those receiving MOUD in other settings, were more likely be 65 years and younger (65% vs 62%; P < .001), less likely to be White (72% vs 82%; P < .001), and more likely to be an urban resident (86% vs 74%; P < .001). When Medicare OTP coverage began, there was no associated drop in the number of dually insured patients with Medicaid with an OTP claim. Of the 1854 OTPs, 1115 (60%) billed Medicare in 2022, with the share billing Medicare ranging from 13% to 100% across states.

Conclusions and relevance: This study showed that since the initiation of Medicare OTP coverage in 2020, there has been a rapid increase in the number of Medicare beneficiaries with claims for OTP services for MOUD, and most OTPs have begun billing Medicare. Patients in OTPs were more likely to be urban residents and members of racial or ethnic minority groups than the patients receiving other forms of MOUD.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
医疗保险对阿片类药物治疗计划的支付。
重要性:自 2020 年 1 月起,医疗保险(Medicare)开始为阿片类药物使用障碍(MOUD)患者在阿片类药物治疗项目(OTP)中配发美沙酮和其他 MOUD 的药物支付费用。目前还很少有研究描述对这一支付变化的反应,以及这一变化是否导致更多患者接受 MOUD,或者仅仅是支付这一治疗费用的人发生了变化:目的:描述有多少医疗保险受益人和哪些医疗保险受益人在开放式门诊接受治疗,以及与在其他医疗机构接受 MOUD 的受益人的比较情况:这项横断面研究包括所有接受 MOUD 治疗的患者,这些患者在 2019-2022 年 100% 美国医疗保险 B 部分和 D 部分报销申请中得到确认。在OTP接受治疗的患者中,也包括在2019-2020年转型医疗补助统计信息系统(Transformed Medicaid Statistical Information System)中获得医疗保险和医疗补助双重保险的患者:主要结果和测量指标:2022年在OTPs治疗的受益人与2022年在其他非OTP机构治疗的受益人的比较:接受OTP治疗的医疗保险受益人比例从2020年1月的万分之四(14 160名受益人)稳步上升至2020年8月的万分之七(25 596名受益人),然后在2022年12月趋于平稳;在2022年接受OTP治疗的38870名患者(23%≥66岁;35%为女性)中,96%接受了美沙酮治疗。与在其他机构接受美沙酮治疗的患者相比,OTP 的患者更有可能是 65 岁及以下(65% 对 62%;P 结论和意义:本研究表明,自 2020 年医疗保险 OTP 开始覆盖以来,申请 MOUD OTP 服务的医疗保险受益人数量迅速增加,大多数 OTP 已开始向医疗保险付费。与接受其他形式 MOUD 的患者相比,OTP 患者更有可能是城市居民和少数民族成员。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.00
自引率
7.80%
发文量
0
期刊介绍: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health, and health care. The journal publishes original research, evidence-based reports, and opinion about national and global health policy. It covers innovative approaches to health care delivery and health care economics, access, quality, safety, equity, and reform. In addition to publishing articles, JAMA Health Forum also features commentary from health policy leaders on the JAMA Forum. It covers news briefs on major reports released by government agencies, foundations, health policy think tanks, and other policy-focused organizations. JAMA Health Forum is a member of the JAMA Network, which is a consortium of peer-reviewed, general medical and specialty publications. The journal presents curated health policy content from across the JAMA Network, including journals such as JAMA and JAMA Internal Medicine.
期刊最新文献
Cannabis Use During Early Pregnancy Following Recreational Cannabis Legalization. Change of Ownership and Quality of Home Health Agency Care. Errors in Conflict of Interest Disclosures. JAMA Health Forum. Surgeon Workforce in Underserved Communities.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1